465 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study is significant because it addresses the complex interplay between inflammatory bowel disease and metabolic health, a common but often unaddressed clinical challenge. The key implication is that a combined t…
This case report is significant because it raises awareness of a potentially novel adverse event associated with tirzepatide, a widely used and highly effective medication. If a causal link were established, it would …
This comprehensive meta-analysis provides compelling and robust evidence that GLP-1 and dual GIP/GLP-1 receptor agonists offer substantial and multifaceted benefits for obese patients with HFpEF, extending significant…
This research highlights the superior patient experience and satisfaction associated with switching to Tirzepatide over escalating Dulaglutide in Type 2 Diabetes management. These findings provide crucial real-world e…
This critical appraisal underscores a crucial safety consideration for tirzepatide, a widely used and highly effective medication for type 2 diabetes and obesity. The identified increased risk of biliary diseases nece…
These findings provide compelling real-world evidence supporting tirzepatide's superior efficacy over sitagliptin not only in glycemic control and weight management but critically, in reducing cardiovascular events in…
The potential success of this combination therapy could represent a significant advancement in the treatment landscape for obesity and overweight. By potentially enhancing the already impressive effects of tirzepatide…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
This Phase II IMPACT-ADT trial is profoundly important as it directly addresses a major unmet need in prostate cancer survivorship, aiming to mitigate the severe cardiometabolic side effects of Androgen Deprivation Th…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to effectively treat Binge-Eating Disorder alongside its established benefits for obesity represents a significant advancement in metabolic and psy…
These findings are highly significant, establishing Tirzepatide as a potentially superior treatment option for individuals with Type 2 Diabetes who are at high risk for cardiovascular events. The dual benefits of subs…
Understanding the precise mechanisms by which Tirzepatide impacts pancreatic alpha and beta cell function and insulin sensitivity is critically important. This mechanistic insight can refine our understanding of optim…
The withdrawal of this study means a potential avenue for exploring enhanced weight loss and metabolic improvements, particularly through muscle preservation with Bimagrumab alongside Tirzepatide's established effects…
Persistent obesity after bariatric surgery represents a significant clinical challenge, often leading to comorbidities and reduced quality of life. If Tirzepatide proves effective and safe in this specific patient pop…
This foundational Phase 1 study is crucial for the development of tirzepatide, providing essential data on its pharmacokinetics and safety in humans. Understanding how the drug is absorbed, distributed, metabolized, a…
This pilot study is critically important as it addresses a significant unmet medical need for safe and effective weight management in obese kidney transplant recipients. Successful outcomes could establish Tirzepatide…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
This study is incredibly significant because it seeks to confirm if tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for weight management, can directly improve long-term health outcomes beyond just…
This research is crucial because it addresses a significant unmet need for effective treatments targeting adiposopathy in a vulnerable population with CKD and Type 2 Diabetes. Understanding how GLP-1RAs impact fat dis…
This research is critical for advancing the use of real-world evidence (RWE) in medical decision-making and drug development. If the emulation successfully replicates the SUMMIT trial's findings, it would validate the…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to address both obesity and methamphetamine use disorder simultaneously represents a significant advancement in addiction medicine and metabolic he…
If these anticipated findings are confirmed, this study could redefine the therapeutic approach to obesity and its metabolic complications, moving beyond mere weight loss to direct reversal of underlying metabolic dys…
Obtaining real-world data on Tirzepatide is paramount for understanding its performance and tolerability outside the highly controlled environment of earlier clinical trials. This study will provide invaluable insight…
The potential to preserve lean mass during GLP-1 induced weight loss is crucial for improving long-term health outcomes and metabolic function in individuals with obesity. Preventing muscle loss can enhance strength, …
If successful, this pilot study could reveal a novel therapeutic application for tirzepatide, potentially offering significant relief for post-menopausal women with obesity suffering from vasomotor symptoms. Beyond sy…
As this is a recruiting clinical trial, specific results are not yet available; however, the study aims to demonstrate significant improvements in key health metrics. Researchers hypothesize that preoperative tirzepat…
This study highlights Tirzepatide's potential as a powerful tool for long-term weight management, particularly for individuals who have already achieved initial success with lifestyle interventions. The ability to not…
The successful integration of tirzepatide with automated insulin delivery could represent a paradigm shift in Type 1 Diabetes management, offering a novel strategy to improve glucose control beyond current capabilitie…
The provided research record is a study protocol description from ClinicalTrials.gov and, as such, does not contain specific efficacy or safety results from the trial. The study, NCT06445075, is listed as COMPLETED, i…
The study aimed to demonstrate that tirzepatide significantly impacts food intake and modulates brain activity in areas associated with appetite and reward. While specific quantitative results are not detailed in this…
This planned study is significant because it aims to explore a novel therapeutic avenue for a highly complex patient population: individuals with obesity and chronic kidney failure. If Tirzepatide demonstrates a favor…
If successful, this study could represent a significant advancement in the treatment of adolescent obesity and its associated health burdens. The potential for tirzepatide to not only reduce weight but also improve ca…
Successfully demonstrating the feasibility and efficacy of tirzepatide for weight loss in early-stage HR+/Her2- breast cancer patients could represent a significant advancement in supportive cancer care. Effective wei…
This Phase 3 trial is highly significant as it directly compares Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, against a standard rapid-acting insulin, insulin lispro (U100), in a challenging patient populatio…
This study is critically important as it will provide a head-to-head comparison of the most effective current treatments for obesity, offering invaluable data for clinical decision-making. If Semaglutide or Tirzepatid…